To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI

Zhejiang University

Status

Completed

Conditions

Cognitive Impairment

Autoimmune Encephalitis

Treatments

Drug: rituximab

Drug: cyclophosphamide

Drug: Intravenous immunoglobulin

Drug: Steroids

Study type

Observational

Funder types

Other

Identifiers

NCT03530462

multi-mode MRIs- encephalitis

Details and patient eligibility

About

Most of patients with autoimmune encephalitis are left with permanent cognitive deficits of varying severity. The patients' life and career would be affected definitely by cognitive deficits. Recently, more and more clinical physician have begun to focus on cognitive impairment of patients with autoimmune encephalitis. Generally, the outcome was measured by the modified Rankin Scale (mRS). However, the mRS are commonly used to evaluate the degree of disability or dependence in the daily activities of the patients suffering from a stroke and cognition function were minimally evaluated in this scale. It is crucial to adopt detailed cognition tools to study the long-term cognitive outcomes and as an indicator of overall curative effect judgment in autoimmune encephalitis.

Currently, only early immunotherapy is uniformly and consistently considered to produce favorable cognitive outcomes. However, studies concerning the association of second-line immunotherapy with cognitive outcomes have been scarce and have shown conflicting results regarding autoimmune encephalitis.

Hence, the goal of this study was to explore cognitive neural mechanism of autoimmune encephalitis by using neuropsychological tests and multi-mode MRIs.

Full description

The goal of this study was to explore cognitive neural mechanism of different types of autoimmune encephalitis by using neuropsychological tests and multi-mode MRIs. Neuropsychological tests involves the assessments of different cognitive domains. And multi-mode MRIs contains resting-fMRI, DTI and task-related fMRI.

Enrollment

22 patients

Sex

All

Ages

16 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Diagnosis was established in all patients based on characteristic clinical presentation and detection of immunoglobulin G (IgG) antibodies.

Exclusion Criteria:

age >60 years or <16 years
notable lesions, such as tumors, scars, or vascular malformations, on brain MRI
a history of other neuropsychiatric disorders. -

Trial design

22 participants in 3 patient groups

patient with first-line and second-line

Description:

patients who received intravenous second-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis),in addition to first-line immunotherapy (rituximab, cyclophosphamide)

Treatment:

Drug: Steroids

Drug: Intravenous immunoglobulin

Drug: cyclophosphamide

Drug: rituximab

patients with first-line only

Description:

patients who received first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis)only

Treatment:

Drug: Steroids

Drug: Intravenous immunoglobulin

healthy control